74 related articles for article (PubMed ID: 16801577)
1. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
Hodis HN; Mack WJ; Zheng L; Li Y; Torres M; Sevilla D; Stewart Y; Hollen B; Garcia K; Alaupovic P; Buchanan TA
Diabetes Care; 2006 Jul; 29(7):1545-53. PubMed ID: 16801577
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
[TBL] [Abstract][Full Text] [Related]
3. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
[TBL] [Abstract][Full Text] [Related]
6. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
8. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
12. Glucose turnover and intima media thickness of internal carotid artery in type 2 diabetes offspring.
Anderwald C; Pfeiler G; Nowotny P; Anderwald-Stadler M; Krebs M; Bischof MG; Kozakova M; Luger A; Pacini G; Roden M; Waldhäusl W
Eur J Clin Invest; 2008 Apr; 38(4):227-37. PubMed ID: 18339003
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
Zhang GY; Yi CG; Li X; Ma B; Li ZJ; Chen XL; Guo SZ; Gao WY
Br J Dermatol; 2009 Apr; 160(4):762-70. PubMed ID: 19120328
[TBL] [Abstract][Full Text] [Related]
14. Correlation of common carotid artery intima media thickness, intracranial arterial stenosis and post-stroke cognitive impairment.
Lee YH; Yeh SJ
Acta Neurol Taiwan; 2007 Dec; 16(4):207-13. PubMed ID: 18220013
[TBL] [Abstract][Full Text] [Related]
15. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
16. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
Xiang AH; Peters RK; Kjos SL; Ochoa C; Marroquin A; Goico J; Tan S; Wang C; Azen SP; Liu CR; Liu CH; Hodis HN; Buchanan TA
J Clin Endocrinol Metab; 2005 Apr; 90(4):1986-91. PubMed ID: 15623809
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
18. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
20. The intake of flavonoids and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study.
Mursu J; Nurmi T; Tuomainen TP; Ruusunen A; Salonen JT; Voutilainen S
Br J Nutr; 2007 Oct; 98(4):814-8. PubMed ID: 17466095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
